Cardio3 BioSciences Appoints Dr. Georges Rawadi as VP Business Development

Cardio3 Biosciences (Paris:CARD) (Brussels:CARD) (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the appointment of Dr. Georges Rawadi as Vice President Business Development.

Leveraging more than 20 years of experience in the healthcare industry, Dr. Rawadi will be responsible for leading C3BS’ worldwide business development efforts, by identifying avenues for growth, international expansion and managing the company’s business partner relationships.

Prior to joining C3BS, Dr. Rawadi served as Vice President Business Development with Cellectis. He previously held business development management positions at Galapagos, ProStrakan France and Sanofi-Aventis France, and conducted consultancy assignments in Business Development and Alliance Management. His work included all aspects and stages of business development, driving several projects from target identification and negotiation to closing deals.

Dr. Rawadi holds a PhD in Microbiology from the Pierre et Marie Curie University (France), and a Masters in Management and Strategy in the Health Industry from the ESSEC Business School.

Dr. Georges Rawadi, VP Business Development, said: "I am excited to join Cardio3 BioSciences and look forward to working with this hugely talented organization.
Cardio3 BioSciences’ pipeline holds great therapeutic potential for significant, currently unmet medical needs.”

Dr Christian Homsy, CEO of Cardio3 BioSciences, commented: "I am delighted to have Dr Rawadi join the executive management team and share his business development expertise as we prepare for the commercialization of our lead product candidate, C-Cure. Dr Rawadi brings a wealth of experience in business and sales strategies, market planning, in- and out-licensing and alliance management, and has a proven track record of building partnerships, identifying, negotiating and closing deals.”

*** END ***

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company’s lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_ez®, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences’ shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.